Novo Nordisk A/S (NVO) Quick Ratio (Acid-Test): 0.57
Is Novo Nordisk A/S’s quick ratio (acid-test) high or low?
Novo Nordisk A/S's quick ratio (acid-test) of 0.57 is in line with its 5-year average of 0.63, near the low end of its 5-year range (0.55–0.69).
As of Wednesday, June 17, 2026. 1.79% above its 12-month average of 0.56.
NVO Quick Ratio (Acid-Test) Chart
NVO Average Quick Ratio (Acid-Test) Chart
NVO Current vs Average Quick Ratio (Acid-Test) Chart
NVO Quick Ratio (Acid-Test) Metrics
QUICK RATIO (ACID-TEST)
0.57
QUICK RATIO (ACID-TEST) AVG TTM
0.56
QUICK RATIO (ACID-TEST) AVG 3Y
0.61
QUICK RATIO (ACID-TEST) AVG 5Y
0.63
QUICK RATIO (ACID-TEST) AVG 10Y
0.75
QUICK RATIO (ACID-TEST) AVG 15Y
0.94
QUICK RATIO (ACID-TEST) AVG 20Y
1.05
CURRENT VS TTM AVG
+1.79%
CURRENT VS 3Y AVG
-6.94%
CURRENT VS 5Y AVG
-9.52%
CURRENT VS 10Y AVG
-24.28%
CURRENT VS 15Y AVG
-39.28%
CURRENT VS 20Y AVG
-45.54%
NVO Competitors' Quick Ratio (Acid-Test)
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Novo Nordisk A/S (NVO) | $193.53B | 0.57 | 0.56 | 0.61 | 0.63 |
| Amgen Inc. (AMGN)vs › | $187.59B | 0.90 | 0.93 | 1.02 | 1.14 |
| Thermo Fisher Scientific Inc. (TMO)vs › | $175.64B | 1.53 | 1.41 | 1.34 | 1.37 |
| Gilead Sciences, Inc. (GILD)vs › | $158.06B | 1.31 | 1.38 | 1.29 | 1.26 |
| Abbott Laboratories (ABT)vs › | $157.84B | 1.18 | 1.21 | 1.20 | 1.26 |
| Pfizer Inc. (PFE)vs › | $148.41B | 0.87 | 0.90 | 0.87 | 0.95 |
| Intuitive Surgical, Inc. (ISRG)vs › | $145.70B | 3.96 | 3.59 | 3.74 | 4.30 |
| Danaher Corporation (DHR)vs › | $128.06B | 1.51 | 1.28 | 1.37 | 1.36 |
| CVS Health Corporation (CVS)vs › | $127.73B | 0.63 | 0.61 | 0.63 | 0.63 |
| Stryker Corporation (SYK)vs › | $119.06B | 1.21 | 1.27 | 1.13 | 1.20 |
Liquidity Comparison
Quick Ratio
0.57
Excludes inventory
Current Ratio
0.80
Includes inventory
Novo Nordisk A/S Quick Ratio (Acid-Test) Formula & Definition
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Novo Nordisk A/S Quick Ratio (Acid-Test) FAQ
- What is the quick ratio (acid-test) for Novo Nordisk A/S (NVO)?
- The quick ratio (acid-test) for NVO stock is 0.57.
- Is Novo Nordisk A/S's quick ratio (acid-test) high or low?
- Novo Nordisk A/S's quick ratio (acid-test) of 0.57 is in line with its 5-year average of 0.63, near the low end of its 5-year range (0.55–0.69).
- What is the TTM average quick ratio (acid-test) for Novo Nordisk A/S (NVO)?
- The TTM average quick ratio (acid-test) for NVO stock is 0.56.
- What is the 3Y average quick ratio (acid-test) for Novo Nordisk A/S (NVO)?
- The 3Y average quick ratio (acid-test) for NVO stock is 0.61.
- What is the 5Y average quick ratio (acid-test) for Novo Nordisk A/S (NVO)?
- The 5Y average quick ratio (acid-test) for NVO stock is 0.63.
- What is the 10Y average quick ratio (acid-test) for Novo Nordisk A/S (NVO)?
- The 10Y average quick ratio (acid-test) for NVO stock is 0.75.
- What is the 15Y average quick ratio (acid-test) for Novo Nordisk A/S (NVO)?
- The 15Y average quick ratio (acid-test) for NVO stock is 0.94.
- What is the 20Y average quick ratio (acid-test) for Novo Nordisk A/S (NVO)?
- The 20Y average quick ratio (acid-test) for NVO stock is 1.05.
Novo Nordisk A/S Quick Ratio (Acid-Test) History
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2025-12-31 | 0.57 |
| 2024-12-31 | 0.55 |
| 2023-12-31 | 0.64 |
| 2022-12-31 | 0.69 |
| 2021-12-31 | 0.66 |
| 2020-12-31 | 0.67 |
| 2019-12-31 | 0.76 |
| 2018-12-31 | 0.79 |
| 2017-12-31 | 0.95 |
| 2016-12-31 | 0.96 |
| 2015-12-31 | 1.04 |
| 2014-12-31 | 1.04 |
| 2013-12-31 | 1.34 |
| 2012-12-31 | 1.42 |
| 2011-12-31 | 1.45 |
| 2010-12-31 | 1.49 |
| 2009-12-31 | 1.69 |
| 2008-12-31 | 1.50 |
| 2007-12-31 | 1.44 |
| 2006-12-31 | 1.22 |
| 2005-12-31 | 1.11 |
| 2004-12-31 | 1.45 |
| 2003-12-31 | 1.47 |
| 2002-12-31 | 1.32 |
| 2001-12-31 | 1.52 |
| 2000-12-31 | 1.33 |
| 1999-12-31 | 1.68 |
| 1998-12-31 | 1.54 |
| 1997-12-31 | 1.91 |
| 1996-12-31 | 1.97 |
Related Metrics
About Novo Nordisk A/S
Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company's operations are structured into two principal business units: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care division delivers therapies for diabetes, obesity, cardiovascular ailments, and other emerging therapeutic areas. Meanwhile, the Rare Disease division concentrates on providing treatments for rare blood disorders, uncommon endocrine conditions, and hormone replacement solutions. In addition to its core pharmaceutical offerings, Novo Nordisk produces specialized medical equipment such as insulin pens, growth hormone pens, and injection needles. It also pioneers smart digital solutions for diabetes management, including advanced insulin pens and the Dose Check application, designed to guide insulin dosage. The company engages in strategic alliances, notably a partnership with UNICEF to combat childhood obesity and a collaboration with Valo Health, Inc. to discover and advance novel drug pipelines in the cardiometabolic space. Founded in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Maziar Mike Doustdar